Dendreon Rises on Optimism Over Cancer Drug Provenge

Dendreon Corp. rose the most in a year on optimism that more patients will begin taking the biotechnology company’s prostate cancer drug Provenge.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.